Despite the availability of pharmacological treatments for cardiac remodeling and HF, including newly recommended angiotensin receptor/neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, and vericiguat, the long-term prognosis remains bleak [21]. This evidence concerns the gene SLC5A2 and hydrops fetalis.